Amphastar (AMPH) Insider Trade: Petersen Disposes 500 Shares
Rhea-AI Filing Summary
Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.
Positive
- Use of Rule 10b5-1 plan underscores strong compliance and reduces perception of opportunistic trading.
Negative
- Insider selling, albeit small, can be perceived as a mildly negative signal by some market participants.
Insights
TL;DR Small 500-share sale (~0.6 % of stake) via 10b5-1 plan; neutral-to-slightly negative signal with minimal impact.
The reported disposition is de minimis for a director holding more than 77 k shares. Use of a Rule 10b5-1 plan mitigates signalling risk because trades were pre-scheduled, but any insider sale can create mild negative sentiment, especially if clustered with other insider activity. No derivatives, no change to beneficial ownership structure, and no other insiders involved, so liquidity impact is negligible. Overall, I classify this event as neutral for valuation, with limited informational value for investors.
TL;DR Pre-planned trade shows compliance discipline; sale size immaterial—impact neutral.
From a governance standpoint, adherence to Rule 10b5-1 demonstrates best practice and reduces litigation risk surrounding insider trading claims. The signature by power of attorney and precise disclosure of weighted-average pricing align with SEC guidance. The transaction does not materially alter the director’s ownership or influence. Accordingly, I view the disclosure as routine housekeeping rather than a directional signal.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 500 | $23.4679 | $12K |
Footnotes (1)
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.335 to $23.625, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
